Long-term safety and efficacy of secukinumab in patients with psoriasis and major psychiatric disorders: a case series.

Long-term safety and efficacy of secukinumab in patients with psoriasis and major psychiatric disorders: a case series. Postgrad Med. 2020 Jan 09;: Authors: Esposito M, Giunta A, Del Duca E, Manfreda V, Troisi A, Bianchi L, Fargnoli MC Abstract Patients with psoriasis are at increased risk for psychiatric comorbidities, including suicidal ideation and behavior. For this reason, a careful assessment of patients, in particular for those reporting history of psychiatric symptoms is needed. We herein report a case series of 3 patients affected by major psychiatric disorders and moderate-to-severe psoriasis, successfully treated with secukinumab, an IL17A inhibitor, with a long-term psychiatric disease stability. PMID: 31916470 [PubMed - as supplied by publisher]
Source: Postgraduate Medicine - Category: Internal Medicine Tags: Postgrad Med Source Type: research